Early launch of Roche’s Ocrevus has surpassed Mavenclad due to first-in-market primary progressive multiple sclerosis label and broad access through compassionate use programs, although transitioning to country-level health plans may slow future momentum, according to a new report from Spherix Global Insights. Neurologists surveyed in Q3 2017 anticipated a 45% prescriber base and 2.5% share of disease-modifying therapy (DMT)-treated patients by this time, but actual Mavenclad use reported by EU neurologists (n=262) has not changed over the past six month.
On March 22nd, UCB Pharma announced that the U.S. FDA approved a label update that includes pharmacokinetic data showing negligible-to-low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant. What impact might this change have for use of the brand by the US physicians managing patients with autoimmune conditions for which Cimzia is indicated?
Ten months after launch, Genentech’s Ocrevus appears to have finally begun to move the needle on the treatment rate for primary progressive multiple sclerosis (PPMS) in the US market. However, with no difference in PPMS treatment rates between Ocrevus prescribers and nonprescribers, it is clear that other market forces are also contributing to the expansion of the treated PPMS patient pool.
Celgene continues to position Otezla in the pre-biologic market segment and has recently disclosed that 80% of commercial lives will now have biologic step-free access to Otezla; but access is only part of the equation. Recent findings from the Q1 update of RealTime Dynamix™: Psoriasis (US) (n=100) reveal that, despite increased access, other factors will largely dictate how much the brand can grow.
The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone. The new psoriasis options have left many US dermatologists slightly overwhelmed, but also excited that their armamentarium is being regularly refreshed, with each new approval arguably boasting skin efficacy rates higher than the last.
An estimated 30 million American adults have CKD and millions of others are at increased risk. Spherix collaborated with 172 nephrologists to analyze 1,059 patient records. The result is an extensive de-identified database containing clinical and non-clinical demographic data including labs, referral practices, underlying cause of CKD, treatment triggers and rates, medication burden, co-morbid conditions, and notable patient history, hospitalizations, and rate of progression - all analyzed by CKD Stage.